早期rhTSH刺激后甲状腺球蛋白预测分化型甲状腺癌预后
本研究纳入299例低至中危分化型甲状腺癌(DTC)患者,在rhTSH刺激下进行清甲前放射性碘治疗(RaIT),测量基础、早期刺激后和晚期刺激后甲状腺球蛋白(Tg)。结果显示早期刺激后Tg是预测卓越疗效(ER)的独立预后标志物,最佳截断值为2.6 ng/mL(AUC=0.931)。
要点
- 早期刺激后Tg预测卓越疗效的AUC为0.931,最佳截断值2.6 ng/mL。
- 早期刺激后Tg是独立于性别、年龄、病理类型等因素的预后标志物。
- 基础Tg的敏感性仅50%,而早期刺激后Tg敏感性达90.9%。
核心结论
- 早期刺激后甲状腺球蛋白是预测DTC初始治疗反应的可靠诊断工具。
研究设计与样本
- 纳入299例低至中危DTC患者,接受rhTSH刺激下清甲前RaIT,测量基础、早期刺激后和晚期刺激后Tg,12个月后按2015 ATA标准评估早期疗效。
主要发现
- 277/299(92.6%)患者达到卓越疗效,15/299(5.1%)为生化不全/不确定反应,7/299(2.3%)为持续结构性疾病。
- 基础、早期刺激后和晚期刺激后Tg预测卓越疗效的最佳截断值分别为1.55(AUC=0.792)、2.6(AUC=0.931)和4.9(AUC=0.874)ng/mL。
- 基础、早期刺激后和晚期刺激后Tg的敏感性分别为50%、90.9%和90.9%,特异性分别为96.7%、84.5%和71.8%,准确性分别为93.3%、84.9%和73.2%,阳性预测值分别为55%、31.7%和20.4%,阴性预测值分别为96.1%、99.1%和99%。
- 单因素和多因素logistic回归分析显示,早期刺激后Tg截断值是预测卓越疗效的独立预后标志物,不受性别、年龄、组织学类型、组织学变异、肿瘤大小、风险分类和疾病分期影响。
关键数值与推荐
- 早期刺激后Tg预测卓越疗效的最佳截断值为2.6 ng/mL(AUC=0.931)。
临床怎么用
- 在rhTSH刺激下清甲前RaIT前测量早期刺激后Tg,有助于预测DTC患者对初始治疗的反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Total thyroidectomy and risk-adapted 131-radioiodine therapy (RaIT) are the treatments of choice in differentiated thyroid cancer (DTC) patients. The response to treatments is assessed 6-12 months after RaIT. However, thyroglobulin (Tg) values obtained just before RaIT also provide reliable informations on patients'outcome. As available data were mostly obtained in hypothyroid status, we evaluated the predictive role of preablation-Tg in patients underwent RaIT after rhTSH stimulation. MATERIAL AND METHODS: We enrolled 299 low-to-intermediate risk DTC patients underwent rhTSH-stimulated RaIT (standard protocol). Serum Tg levels were measured before rhTSH administration (basal Tg), before RaIT (early-stimulated Tg), and 2 days after RaIT (late-stimulated Tg). The early response assessment was done 12 months after RaIT according to 2015 American Thyroid Association (2015 ATA) criteria. RESULTS: Most patients (277/299, 92.6%) had an excellent response (ER) to RaIT, while 15/299 (5.1%) and 7/299 (2.3%) patients showed biochemical incomplete/indeterminate response or persistent structural disease, respectively. At receiver operating characteristic analysis, the optimal cutoff to predict ER was set at 1.55 (AUC = 0.792), 2.6 (AUC = 0.931), and 4.9 (AUC = 0.874) ng/mL, for basal, early-, and late-stimulated Tg, respectively. The overall sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) for basal, early-, and late-stimulated Tg were 50%, 96.7%, 93.3%, 55%, and 96.1%; 90.9%, 84.5%, 84.9%, 31.7%, and 99.1%; and 90.9%, 71.8%, 73.2%, 20.4%, and 99%, respectively. In univariate and multivariate logistic regression analysis, early-stimulated Tg cutoff resulted as an independent prognostic marker for predicting ER regardless of gender, age, histotype, histological variant, tumor size, risk classification, and stage of disease. CONCLUSION: Early-stimulated Tg is a reliable diagnostic tool for predicting the response to primary treatment of DTC.
引用
- Campennì A, Ruggeri RM, Siracusa M, et al. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 33416957. doi:10.1007/s00259-020-05153-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。